The shadow of generic rivalry has repeatedly loomed above copyright’s famous drug, PDE5 Inhibitor, raising questions about the outlook of connected drug stakes. While early years saw significant profits, the patent end has allowed the door for discounted substitutes, likely diminishing earnings and presenting a real hazard for stakeholders looki… Read More